Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of p-glycoprotein alterations in treatment-resistant depression: a [18F]MC225 PET study
2023-508303-20-01Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 18F-MC225 in major depressive disorder (MDD) and treatment-resistant depression (TRD) (2 arms), sponsored by Policlinico Gemelli. Planned start Apr 2025; status: authorised.
02
Drugs
18F-MC225
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2023-508303-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508303-20-01.